Comparisons of CT features and <sup>18</sup>F-FDG metabolic indices between benign and malignant entities, as well as among primary and secondary malignancies and lymphoma, were performed.
We retrospectively reviewed F-FDG PET/CT studies of 117 patients (169 lesions), of which 65 had imaging of enostoses, and 52 had imaging showing the transition of lesions from untreated to treated osteoblastic metastases.
Comparison of <sup>18</sup>F-FDG PET/MRI, MRI, and <sup>18</sup>F-FDG PET/CT for the detection of synchronous cancers and distant metastases in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma.
Vice versa, highly F-FDG-avid lung lesions in patients with brain tumors should lead to distant metastases as differential diagnosis despite their rare occurrence.
<b>Conclusions and significance:</b><sup>18</sup>F-FDG PET/CT or conventional imaging is comparable with regard to detecting distant metastases of recurrent HNSCC.
Data from studies comparing PET/MRI and PET/CT for staging/restaging suggested the superiority of <sup>18</sup>F-FDG PET/MRI for the detection of tumour extension and retropharyngeal lymph node metastases in nasopharyngeal cancer, and for the detection of liver metastases and possibly bone marrow metastases in high-risk BC.
The purpose of this study is to prospectively evaluate the performance of sodium <sup>18</sup>F]fluoride (Na[<sup>18</sup>F]F)/2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers.
A range of parameters including volumetric and heterogeneity measures were derived from FDG PET images of 52 patients with colorectal intrahepatic-only metastases (29 males and 23 females; mean age 62.9 years [SD 9.8; range 32-82]).
[<sup>18</sup>F]Fluorodeoxyglucose ([<sup>18</sup>F]FDG) Positron emission tomography/computed tomography (PET/CT) is commonly used for rectal cancer staging, but improved diagnostic methods for nodal metastases are needed.
However, <sup>18</sup>F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial <sup>18</sup>F-FDG PET/CT scanning.
No differences between metachronous cancers and metastases were found in: patient's age (70.3±8.1years vs 69.5±9.7years), gender (males=63.1% vs 62.5%), interval between previous cancer diagnosis and nodules' detection (median time=4years vs 4.5years), location (right-lung=55% vs 54%; upper-lobes=64% vs 67%; central-site=31% vs 25%), size (median size=17mm vs 19.5mm), 18F-FDG standardized uptake value (median SUVmax=5.2 vs 5.9).
<sup>18</sup>F-Fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET-CT) is frequently used to assess primary tumor and distant metastases but provides information on lymph node status as well.
SUV<sub>max</sub> ratio between the cardiac focus and surrounding background cardiac uptake and status of distant metastases might help to differentiate malignant from benign nature of the focal cardiac uptake on FDG PET/CT.
This study assesses <sup>18</sup>F-FDG PET/CT systemic staging in patients with newly diagnosed male breast cancer and determines detection rates for unsuspected distant metastases stratified by pre-PET/CT stage.
Fluorodeoxyglucose-positron emission tomography (FDG-PET) showed FDG uptake not only in the pelvic tumor but also in the hepatic nodule, thus suggesting metastases.
Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481).F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC.
Clinical usefulness of <sup>18</sup>F-FDG PET/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis.
The secondary outcome measure was the proportion of patients in whom 18F-FDG PET(/CT) restaging was false positive for distant interval metastases (i.e. false positives).
This report describes how an 18F-FDG misadministration led to a repeat PET/CT study, resulting in the visualization of distant metastases that changed the original treatment plan.